Rheumatoid arthritis is a common autoimmune disease with a complex genetic etiology. Here we identify a SNP in the promoter region of FCRL3, a member of the Fc receptor-like family, that is associated with susceptibility to rheumatoid arthritis (odds ratio = 2.15, P = 0.00000085). This polymorphism alters the binding affinity of nuclear factor-jB and regulates FCRL3 expression. We observed high FCRL3 expression on B cells and augmented autoantibody production in individuals with the disease-susceptible genotype. We also found associations between the SNP and susceptibility to autoimmune thyroid disease and systemic lupus erythematosus. FCRL3 may therefore have a pivotal role in autoimmunity.
Rheumatoid arthritis is one of the most common autoimmune diseases and is characterized by inflammation of synovial tissue and joint destruction. Although the disease is believed to result from a combination of genetic and environmental factors, its complete etiology has not yet been clarified 1 . Specific haplotypes of human leukocyte antigen (HLA)-DRB1, usually referred to as shared-epitope sequences 2 , have been repeatedly reported to confer susceptibility to rheumatoid arthritis 3, 4 ; other genetic components are also involved 5 . This combination of HLA haplotypes and non-HLA genes accounting for disease susceptibility is also observed for other autoimmune diseases [6] [7] [8] . In autoimmune thyroid disease (AITD), for instance, the HLA-DR3 haplotype is associated with disease risk, as is a functional haplotype of a non-HLA gene, CTLA4, that has recently been associated with AITD susceptibility 9 .
Identification of non-HLA genes associated with rheumatoid arthritis susceptibility and other autoimmunities seems difficult, because of the low relative risk of disease resulting from these non-HLA genes compared with the strong relative risk from diseaseassociated HLA haplotypes. In a search for non-HLA determinants of disease susceptibility, whole-genome studies have been done for both human autoimmune diseases and experimental animal models. These studies have identified nonrandom clustering of susceptibility loci for clinically distinct diseases 8, 10 . The overlap of susceptibility loci for multiple autoimmunities suggests that common susceptibility genes exist in those regions. Intense studies of loci-clustering regions identified genes commonly associated with multiple autoimmune diseases, such as CTLA4 on 2q33 (ref. 9 ), SLC22A4 and SLC22A5 on 5q31 (ref. 11 ) and PTPN22 on 1p13 (ref. 12) .
Cytoband 1q21-23 is one of the regions implicated in susceptibility to multiple autoimmune diseases. The Fcg receptor (FcgR) II/III genes are located at 1q23, and a new family of genes, Fc receptor-like genes (FCRLs, also known as FcRHs 13, 14 , IRTAs 15, 16 or SPAPs 17 ) , clusters nearby at 1q21 (Fig. 1a) . FCRLs have high structural homology with classical FcgRs, although their ligands and function are not yet known. These receptors are good candidates for involvement in autoimmunity, as they are believed to be involved in the pathogenesis of rheumatoid arthritis and other autoimmune diseases 18 . Region 1q23 is a candidate locus for susceptibility to systemic lupus erythematosus (SLE), and variants in the classical FcgR II/III genes partially account for disease susceptibility 6, 19 . Region 1q21 is a candidate locus for susceptibility to psoriasis (PSORS4; refs. 7, 20) and multiple sclerosis 21 . The mouse homologous region to human 1q21, on chromosome 3, also contains susceptibility loci for multiple autoimmune disease models 8 25) ). Although 1q21-23 is a good candidate region for containing rheumatoid arthritis-susceptibility genes, the association of classical FcgRs with disease susceptibility remains controversial 26, 27 . Here we focused on the 1q21-23 region to identify rheumatoid arthritisassociated genes in Japanese subjects using linkage disequilibrium (LD) mapping.
RESULTS
Case-control study by SNP-based LD mapping at 1q21-23 To evaluate the extent of association, we analyzed LD with SNPs distributed in a 16-Mb region on 1q21-23, including the FCRL gene cluster and the classical FcgRs (Fig. 1a) . We genotyped 658 control subjects for 742 SNPs from the JSNP database and selected 491 SNPs with allele frequency 40.1, successful genotyping rate 40.95 and P 4 0.01 with Hardy-Weinberg equilibrium testing for evaluation of LD. We calculated the pairwise LD index D (ref. 28) for each pair of SNPs, identifying 110 LD blocks 11 at a threshold of D 4 0.5 (Fig. 1a) .
For association testing, we examined the Japanese set of 830 cases and 658 controls used for LD block evaluation. We initially genotyped 94 rheumatoid arthritis cases for 491 SNPs and compared their allele frequencies with those of 658 control subjects. We identified nine SNPs that had allele frequencies differing by more than 0.1 between 658 controls and 94 cases with P o 0.01. We genotyped the remaining cases for these nine SNPs and tested their allele frequencies for casecontrol association. We identified the smallest P value between an intronic SNP in the gene FCRL3 and rheumatoid arthritis (fcrl3_6, P ¼ 1.8 Â10 À5 ; association was statistically significant in both rheumatoid arthritis subgroups (94 and 736 individuals)). This SNP was located in a LD block containing four of the five FCRL genes; the fifth was in the adjacent block. We therefore evaluated the origin of this association in these two LD blocks (Fig. 1b) , although our results do not exclude the presence of variants associated with rheumatoid arthritis or other autoimmune diseases in other LD blocks at 1q21-23.
In addition to the 25 SNPs of the 491 that we used for LD block evaluation, we identified 16 additional SNPs in exons and 5¢ and 3¢ flanking regions of five FCRL genes and one pseudogene (FCRLc4) by searching the public database and sequencing genomic DNA from Japanese individuals with rheumatoid arthritis. We genotyped these 16 SNPs in the identical case and control samples (830 cases, 658 controls) to increase the density of variants in the targeted region. We observed a peak of association in a short segment consisting of four SNPs in FCRL3 (P o 1.0 Â10 À4 ; Fig. 1c and Supplementary Table 1 online): fcrl3_3, fcrl3_4, fcrl3_5 and fcrl3_6, located at nt À169, À110, +358 (5¢ untranslated region of exon 2) and +1381 (intron 3; 204 bp and 859 bp from the 3¢ and 5¢ ends of the flanking exons) relative to the transcription initiation site, respectively.
We observed the smallest P value without correction in recessivetrait genotype comparison of fcrl3_3 in FCRL3 (P ¼ 8.5 Â10 À7 ; odds ratio ¼ 2.15; 95% confidence interval ¼ 1.58-2.93; Table 1 ). This P value was still significant when the most conservative Bonferroni correction was applied (comparisons for 507 SNPs; corrected P ¼ 0.00043). The four strongly associated SNPs were in LD with each other, and we inferred three common haplotypes ( Table 2) ; fcrl3_3, fcrl3_5 and fcrl3_6 showed strong LD with each other (D 4 0.99), whereas fcrl3_4 showed relatively weak LD with the other three SNPs (mean D ¼ 0.68).
To identify causal variants in this segment on the basis of genotype data, we carried out a forward stepwise-regression procedure with a cut-off P value to proceed to the next step of 0.01 (ref. 29) . No SNP in FCRL genes other than FCRL3 improved the model. None of the four SNPs in FCRL3 were preferred over the others in these data (data not shown). This result implied that one of the SNPs in FCRL3 might cause the disease, but the possibility remained that variants in other genes were truly associated with the disease.
To validate the case-control association test, we evaluated the impact of population stratification on the case-control study (830 cases, 658 controls). We selected 2,069 SNPs, each of which was identified as a tagging SNP 30 in 2,069 distinct LD segments that were previously identified by genotyping 74,842 SNPs distributed in autosomal chromosomes 31 . We analyzed population structure 32 and the w 2 sum 33 to evaluate stratification but detected no significant evidence of population stratification ( Supplementary Fig. 1 online) . These results are suggestive of no or negligible stratification of our samples and support the validity of the case-control association results by removing this confounding factor from further consideration.
Regulatory effect of SNP -169C-T on FCRL3 expression Because none of the four SNPs in FCRL3 (fcrl3_3, fcrl3_4, fcrl3_5 and fcrl3_6) produces amino-acid substitutions, we assessed potential effects of the SNPs on transcription factor binding using TRANSFAC software. Nuclear factor-kB (NF-kB) was predicted to bind the sequence containing the rheumatoid arthritis-susceptibility allele fcrl3_3 (À169C) with a high score (core match 1.000, matrix match 0.957); substitution with the nonsusceptible allele T decreased the score of NF-kB binding substantially (core match 0.760, matrix match 0.824). The other three SNPs were not predicted to bind to any transcriptional factor with high score, and nucleotide substitution was not predicted to affect binding at any regulatory factor. We therefore focused on the 5¢ flanking region of fcrl3_3 to explore the regulatory effects on expression of FCRL3.
We carried out reporter gene analysis using the genomic sequence of FCRL3 from nt À523 to +203. We made constructs corresponding to the three haplotypes using SNPs at nt À169 (C-T, fcrl3_3) and À110 (G-A, fcrl3_4; Fig. 2a ) and used them to transfect Raji cells, a Burkitt's lymphoma cell line that expresses FCRL3 (ref. 13 ) and is derived from germinal center B cells. Luciferase activity was substantially greater in cells transfected with À169C À110G or À169C À110A constructs than in cells transfected with À169T À110G constructs. This suggests that SNP À169C-T is crucial for regulation of FCRL3 expression. To clarify, we cloned single or four tandem copies of 30-bp oligonucleotides surrounding SNP À169C-T and control oligonucleotides into a vector with the SV40 promoter. Cells transfected with a single copy of the C allele produced substantially greater luciferase activity than cells transfected with a single copy of the T allele. More convincingly, transfection with four tandem copies of the C allele enhanced luciferase activity by a factor of 20 over transfection with four tandem copies of the T allele (Fig. 2a) .
To elucidate specific nuclear factors that bind the disease-susceptible allele, we analyzed the sequence around À169C-T. These sequences were predicted by TRANSFAC software to have binding affinity for NF-kB, which regulates a wide variety of genes in the immune system. The disease-susceptible sequence (including À169C) had higher matrix similarity to the consensus NF-kB binding motif than the nonsusceptible sequence (including À169T). We then carried out electrophoretic mobility shift assays (EMSAs) to examine whether differences between the susceptible À169C allele and the nonsusceptible À169T allele affected binding of nuclear proteins from Raji cells. We used the same 30-bp labeled oligonucleotides used in the luciferase assay. These sequences contain the predicted NF-kB binding site. We observed two main bands, I and II, in the presence of nuclear extracts; the intensity of band I was higher for the susceptible À169C allele than for the nonsusceptible À169T allele (Fig. 2b) . Competition assays with unlabeled oligonucleotides indicated that these complexes were specific for the probes. In addition, competition assays with unlabeled probes of the C allele for T and the T allele for C showed that the C allele was better able to compete for binding, a result consistent with the higher binding affinity of labeled C allele probes alone. We also carried out a supershift experiment with antibodies specific for NF-kB components (p50, p52, p65, RelB and cRel). We observed supershifts in some lanes with specific antibodies for p50, p65 and cRel (Fig. 2b) . Among these, only antibody to p50 shifted band II, suggestive of the presence of a p50-p50 homodimer. Band I had the highest intensity and a substantial allelic difference and was supershifted by antibodies to p50, p65 and cRel. Although these findings indicate that band I comprises a mixture of heterodimers, the greater shifts caused by antibodies to p50 and cRel suggest that the main component is a p50-cRel heterodimer.
The two in vitro assays showed the potent transcriptional activity of the disease-susceptible haplotype regulated by NF-kB, suggesting that expression of FCRL3 is greater from the disease-susceptible À169C allele than from the nonsusceptible À169T allele. To extend these findings, we quantified expression of FCRL3 in peripheral blood B cells from healthy donors using quantitative TaqMan methods and analyzed the effect of the number of susceptible copies on the transcript level by regression model. Regression analysis identified a significant positive correlation between number of susceptible chromosomes and transcription level (R 2 ¼ 0.49, P ¼ 0.0076; Fig. 2c) .
We also carried out allele-specific transcript quantification 9, 34 to confirm the effect of the SNP on transcription. Using an EagI restriction-fragment length polymorphism located at position +358 in exon 2 of FCRL3 (fcrl3_5, +358C-G), we measured the relative contribution of each haplotype to transcript production in heterozygous individuals (Fig. 2d) . We evaluated the transcripts of five doubly heterozygous individuals with genotype À169C/T +358C/G; the mean ratio (susceptible versus nonsusceptible haplotype) was 1.63, significantly higher than that of DNA amplicons (ratio ¼ 1.06, P o 1 Â10 À5 ) from the same individuals. (The quantity of template DNA from the two haplotypes was equal.) These results show that the (c) Relative expression of FCRL3 in response to stimuli (antibody to CD40, 1 mg ml À1 ; antibody to IgM, 1 mg ml À1 ; IL-4, 10 ng ml À1 ; APRIL, 10 ng ml À1 ; BAFF, 10 ng ml À1 ; LPS, 100 ng ml À1 ) for 4 h. Representative data from three experiments done in triplicate. (d,e) Lymphocyte aggregates in rheumatoid arthritis synovium. T cells and B cells in serial sections were immunostained using antibodies to CD3 (d) and CD20 (e), respectively. (f,g) FCRL3 mRNA expression (blue stain) in rheumatoid arthritis synovium as analyzed by in situ hybridization. Higher magnification views of synovium (g) are denoted by the box in f (magnifications: d-f, Â100; g, Â400). Counterstaining: d,e, hematoxylin; f,g, nuclear fast red. expression of FCRL3 is higher in individuals with the disease-susceptible haplotype and suggest that higher expression of FCRL3 is a potential cause and component of the pathological mechanism(s) leading to rheumatoid arthritis.
Expression of FCRL3 mRNA
We then quantified FCRL3 expression in multiple tissues using TaqMan methods. Expression of FCRL3 transcripts was high in the spleen and tonsils (Fig. 3a) , which are secondary lymphoid organs. We observed lower expression in thymus and bone marrow. In human blood fractions, CD19 + cells, which represent the B-cell population, had the greatest FCRL3 expression among peripheral blood mononuclear cells. CD4 + and CD8 + cells had less expression (Fig. 3b) . We next examined the effect of B-cell stimulation on FCRL3 expression. We cultured peripheral blood B cells from a healthy donor for 4 h using known B-cell stimulants and then quantified FCRL3 mRNA (Fig. 3c) . Expression of FCRL3 was increased by antibody to CD40 and lipopolysaccharide (LPS). We then investigated expression of FCRL3 transcripts in synovial tissue using in situ hybridization methods. T and B cells are the key players with regard to inflammation in synovial tissue, producing proinflammatory cytokines and autoantibodies that might be pathogenic 1 . These cells show three distinct histological patterns: diffuse infiltration, clustering in aggregates and follicles with germinal-center reaction 35, 36 . We observed aggregations of T and B cells in paraffinembedded synovial sections from individuals with rheumatoid arthritis, using immunostaining with antibodies to CD3 and CD20, respectively (Fig. 3d,e) . In situ hybridization assay with serial sections detected FCRL3 mRNA in aggregated lymphocytes (Fig. 3f,g ). Although strict differentiation between B and T cells was difficult, at least some aggregated B cells were positive, with strong expression of FCRL3 mRNA. Synovium from two other individuals with rheumatoid arthritis had similar lymphocyte aggregates and FCRL3 expression ( Supplementary Fig. 2 online) .
SNP association with autoantibody and HLA-DRB1 status Because we suspected that higher FCRL3 expression led to B-cell abnormalities in rheumatoid arthritis, we examined associations in individuals with rheumatoid arthritis between genotype and two rheumatoid arthritis-related autoantibodies: rheumatoid factor (RF) and antibody to cyclic citrullinated peptide (CCP). RF is a well-known autoantibody for the Fc region of IgG, and titers correlate with rheumatoid arthritis disease activity 37 . Antibody to CCP recognizes peptides containing citrulline and is detected in rheumatoid arthritis with extremely high specificity 38, 39 . RF titer in individuals with rheumatoid arthritis was significantly positively correlated with the number of susceptible alleles (R 2 ¼ 0.049, P ¼ 0.0065; Table 3 ). The positive ratio of antibody to CCP in individuals with rheumatoid arthritis also differed significantly among genotypes (P o 0.05) and correlated with number of susceptible alleles.
Because genetic interactions between HLA and non-HLA loci have been described in susceptibility for rheumatoid arthritis and other autoimmune diseases 26, 40 , we compared genotype distributions for SNP À169C-T among three rheumatoid arthritis subgroups stratified by number of HLA-DRB1 shared-epitope alleles. We previously genotyped HLA-DRB1 in our population and observed significant associations between rheumatoid arthritis susceptibility and sharedepitope alleles 4 . Allele frequency of the rheumatoid arthritissusceptibility allele À169C was significantly higher in the subgroup with two copies of shared-epitope alleles (0.49, n ¼ 113) than in the subgroup with no shared-epitope alleles (0.39, n ¼ 215; P o 0.05).
Replication study of association in three autoimmunities
To confirm associations between the FCRL3 variant and rheumatoid arthritis susceptibility, we carried out a replication study (540 individuals with rheumatoid arthritis, 636 controls). We compared allele frequency and found a significant association between fcrl3_3 (À169C-T) and rheumatoid arthritis susceptibility (allele frequency was 0.40 in individuals with rheumatoid arthritis versus 0.46 in controls; P ¼ 0.041; Supplementary Table 2 online). We noted no significant differences between two cohorts that consisted of the replication samples. These results further confirmed the association of the fcrl3_3 À169C allele with rheumatoid arthritis susceptibility in Japanese individuals.
Because this region is associated with multiple autoimmune diseases, and because several variants are involved in multiple autoimmunities, we investigated associations between SNP À169C-T and two other autoimmune diseases: AITD and SLE. We recruited 509 Japanese individuals with AITD (351 with Graves' disease and 158 with Hashimoto's thyroiditis) and 564 Japanese individuals with SLE and compared them with 2,037 Japanese controls. In addition, we combined AITD, SLE and rheumatoid arthritis cases as subjects with an autoimmune phenotype and tested for associations with the SNP. Individual diseases, as well as combination of two AITDs and combination of AITD, SLE and rheumatoid arthritis, were significantly associated with the SNP (odds ratio ¼ 1.52, P ¼ 0.00000084 in Japanese for a recessive model between all four autoimmunities considered in aggregate and controls; Table 4 ). As rheumatoid arthritis-specific autoantibodies were correlated with the number of susceptible alleles, antibody to DNA titer was higher in individuals with SLE with genotype À169C/C than in subjects with other genotypes (294.1 IU ml À1 versus 145.5 IU ml À1 ; n ¼ 120; P ¼ 0.026 by Student's t-test), a conclusion not further established by regression analysis (P ¼ 0.12). 12 whereas others are widely dispersed but significantly associated with disease in only specific ethnic groups 41, 42 . We evaluated four-SNP haplotypes in FCRL3 in African American, European American and Asian (Korean and Japanese) subjects and found weaker LD in African Americans than in other groups and substantial differences in allelic frequency among the groups (Supplementary Table 3 online).
Although the evidence presented here for FCRL3 being an autoimmune disease-susceptibility gene is powerful, additional autoimmune disease-related genes probably exist in this region. For example, 1q23 is a good candidate locus for SLE susceptibility 6 , particularly involving the association of the classical FcgR genes with SLE susceptibility in the Japanese population 19 , although those variants are not in LD with SNP À169C-T in our Japanese subjects (D o 0.05, Fig. 1a) . Multiple SLE susceptibility genes are also homologous to human 1q23 in mouse models of SLE 43 .
Further evaluation of polymorphism associations showed that a SNP in the promoter region of FCRL3 alters expression of FCRL3 through NF-kB binding. Because higher expression of FCRL3 was observed in individuals with susceptible alleles, and augmented autoantibody production was associated with the susceptible genotype, important steps in the sequence of events leading to autoimmunity must proceed through FCRL3. That the susceptible allele is associated with HLA-DRB1 in rheumatoid arthritis is consistent with FCRL3 functioning in the context of HLA class II restriction, which is usually seen in the interaction between T cells and antigen-presenting cells, including B cells. Moreover, together with the dominant expression of FCRL3 on B cells and the importance of B cells suggested by a recent clinical trial of B cell-depleting therapy 44 , the present findings might provide a genetic basis for B-cell abnormality in autoimmunity.
Although the precise function of FCRL3 is unknown, its predicted molecular structure suggests that it is a membranous protein that conveys signals into cells through a cytoplasmic domain containing an immunoreceptor-tyrosine activation motif and an immunoreceptortyrosine inhibitory motif 14 . An in vitro study showing the binding of tyrosine kinases syk and ZAP70 to the immunoreceptor-tyrosine activation motif region and of tyrosine phosphatases SHP-1 and SHP-2 to the immunoreceptor-tyrosine inhibitory motif region 17 supports the proposed signaling function of FCRL3. In a previous study examining in situ hybridization in human tonsil, FCRL3 was expressed in the germinal center, with particularly high expression in the light zone 16 , suggesting that FCRL3 functions predominantly in centrocytes. The present finding that CD40 stimulation, which is important in germinal-center formation 45 , upregulates FCRL3 expression in B cells could indicate that FCRL3 is specifically expressed in germinal-center centrocytes under the influence of CD40 signals. In the light zone, centrocytes undergo clonal selection and affinity maturation regulated by positive and negative signals from antigen receptors and coreceptors 46 . High expression of FCRL3 and augmented autoantibody production in individuals with the diseasesusceptible genotype is consistent with the idea that FCRL3 influences the fate of B cells and augments the emergence of self-reactive cells in the germinal center.
In addition to its role in lymphoid tissues, expression of FCRL3 in synovial tissue might explain the pathological connection between FCRL3 variants and rheumatoid arthritis. FCRL3 is strongly expressed in aggregated lymphocytes. Although our synovial samples showed only T-cell-B-cell aggregates, lymphocytes in rheumatoid arthritis synovial tissue are known to form a germinal center-like structure, called an ectopic germinal center, where T cell-dependent antibody production and affinity maturation occur 36 . Ectopic germinal-center formation also occurs in tissues from individuals with AITD and SLE, and FCRL3 might be involved in pathological autoimmune reaction in these disease-specific ectopic lymphocyte aggregates.
Considering that augmented expression of FCRL3 is associated with susceptibility to autoimmune disorders, and that FCRL3 expression is regulated in B cells in the secondary lymphoid organ and is detected in lymphocytes of disease-specific tissues, FCRL3 probably functions in immunity and potentially pathogenic in autoimmune disorders.
METHODS
Subjects. We enrolled three independent cohorts of individuals with rheumatoid arthritis (n ¼ 830, 217 and 323), a cohort of individuals with SLE (n ¼ 564) and a cohort of individuals with AITD (n ¼ 509) comprising Graves' disease (n ¼ 351) and Hashimoto's thyroiditis (n ¼ 158) through several medical institutes in Japan. We recruited four independent cohorts of unaffected control subjects (n ¼ 658, 262, 374 and 752) at various sites in Japan. All subjects were Japanese. Individuals with rheumatoid arthritis (84.2% women; age 59.0 7 12.3 years (mean 7 s.d.); 75.0% RF-positive) satisfied the revised criteria of the American Rheumatism Association for rheumatoid arthritis 47 . Individuals with SLE satisfied the criteria of the American College of Rheumatology for SLE 48 We evaluated LD at 1q21-23 in the first control cohort compared with the first rheumatoid arthritis cohort to identify the rheumatoid arthritis-associated LD block and SNPs. The second and third rheumatoid arthritis and control cohorts were used for replication testing of results from the first cohorts. We tested Graves' disease; Hashimoto's thyroiditis; SLE; the combination of the two AITDs; and the combination of rheumatoid arthritis, SLE and the two AITDs for associations using the total pool of controls. We enrolled control subjects from three other ethnic groups, Korean (n ¼ 100), African American (n ¼ 120) and European American (n ¼ 120), for evaluation of FCRL3 haplotypes. We sampled synovial tissues from individuals with rheumatoid arthritis who underwent arthroplastic surgery. All subjects provided informed consent to participate in the study, as approved by the ethical committee of the SNP Research Center, RIKEN.
SNPs and genotyping. We identified SNPs in exons and 5¢ and 3¢ flanking regions of FCRL1, FCRL2, FCRL3 and FCRLc4 by direct sequencing of DNA from 24 individuals. We selected other SNPs from the JSNP and Assay-OnDemand SNP databases (Applied Biosystems). We genotyped SNPs using Invader and TaqMan assays 41 as indicated by the manufacturers. Probe sets for the Invader assay were designed and synthesized by Third Wave Technologies, and those for the TaqMan assay were obtained from Applied Biosystems. When assessing the results of SNP genotyping, we generally excluded successful call rates o0.95 and values of P o 0.01 obtained by Hardy-Weinberg equilibrium testing in control subjects. The error rate of Invader assay was 0.0023, which was estimated by 11,092 assays in two replicates using 118 randomly selected SNPs (internal control data).
Luciferase assay. We cloned the promoter fragment of three haplotypes corresponding to nt À523 to +203 of FCRL3 into the pGL3-Basic vector (Promega). We generated oligonucleotides using the allelic sequences of nt À189 to À160 of FCRL3. We cloned a single copy or four tandem copies of these oligonucleotides into pGL3-Promoter vector (Promega). We grew Raji cells (RCB1647; RIKEN Cell Bank) in RPMI1640 medium supplemented with 10% fetal bovine serum and antibiotics. We electroporated (230 V and 975 mF) 1 Â10 7 cells with 5 pmol of constructs and 1 pmol of pRL-TK vector (internal control for transfection efficiency) in a 0.4-cm gap cuvette. After 48 h, we collected cells and measured luciferase activity using the Dual-Luciferase Reporter Assay System (Promega).
EMSA. We carried out EMSA and preparation of nuclear extract from Raji cells as previously described 49 . We labeled oligonucleotides À169T and À169C with digoxigenin -11-ddUTP using the DIG gel-shift kit (Roche). We incubated 5 mg of nuclear extract with 40 fmol of digoxigenin-labeled nucleotide for 25 min at room temperature. For competition experiments, we preincubated nuclear extract with unlabeled oligonucleotide (100-fold excess) before adding digoxigenin-labeled oligonucleotide. For supershift assays, we incubated 4 mg of antibodies to p50, p52, p65, RelB or cRel and rabbit IgG (control antibody; Santa Cruz Biotechnology) for 15 min at room temperature after incubation of the labeled probe. We separated protein-DNA complexes on a nondenaturing 6% polyacrylamide gel in 0.5Â Tris-Borate-EDTA buffer. We transferred the gel to a nitrocellulose membrane and detected signals using an LAS-3000 luminoimage analyzer (Fujifilm).
RNA extraction and cDNA preparation. We collected peripheral blood from healthy volunteers to obtain CD19 + lymphocytes. We separated polymorphonuclear cells by differential centrifugation using Lymphoprep resolving solution (AXIS-FIELD). We isolated CD19 + lymphocytes using the MACS system with CD19 microbeads (Miltenyi Biotec) and confirmed that cell purity was 495% using flow cytometry. We stimulated cells with antibodies to CD40 (Cymbus Biotechnology) or IgM (Jackson Immunoresearch), with Il-4 (eBioscience), with APRIL (PeproTech), with BAFF (PeproTech) or with LPS (Sigma) for 4 h. We isolated total RNA using RNeasy Mini Kit (Qiagen). We quantified RNA in other normal tissues using Premium Total RNA (Clontech). We reverse-transcribed total RNA using TaqMan Gold RT-PCR reagents with random hexamers (Applied Biosystems) in accordance with the instructions of the manufacturer.
Quantification of FCRL3 expression using real-time RT-PCR. We carried out real-time quantitative PCR using an ABI PRISM 7900 (Applied Biosystems) and Assay-on-Demand TaqMan probe and primers (Hs00364720_m1 for FCRL3) in accordance with the manufacturer's instructions. We generated a standard curve from the amplification data for FCRL3 primers using a dilution series of total RNA from Raji cells as templates and normalized data to GUS level.
ASTQ. We carried out ASTQ as previously described 34 with some modifications. We prepared cDNA from B cells as described above. We amplified both cDNA and genomic DNA by PCR for 37 cycles using primers specific for exon 2 of FCRL3 (Supplementary Table 4 online) and for an additional cycle using forward primer with Alexa Fluor 488 label at the 5¢ end. Products were directly digested using EagI by incubation at 37 1C for 12 h. We monitored full digestion by the inclusion of PCR products from +358G/G homozygotes. We then separated digested products on a 12.5% polyacrylamide gel and quantified them using an LAS-3000 analyzer.
In situ hybridization and immunohistochemistry. We carried out in situ hybridization as previously described 50 . We obtained probes from PCR products using the sequence of FCRL3 (nt 2052-2490, comprising the intracellular unique region that is poorly conserved among members of this family). An additional probe of the 5¢ untranslated sequence yielded similar results. We also examined control probes, which yielded no specific hybridization (data not shown). We used antibodies to CD3 (clone PS-1, Nichirei) and CD20 (clone L26, Zymed) for immunohistochemistry with an ABC Elite kit (Vector Labs) in accordance with the manufacturer's instructions. No specific staining was detected using mouse isotype IgG (data not shown).
Measurement of autoantibodies.
We measured RF in sera of individuals with rheumatoid arthritis using latex-enhanced immunonephelometric assay. We measured antibody to DNA in sera of individuals with SLE by radioimmunoassay. Individuals with rheumatoid arthritis (n ¼ 147, 81.1% women; age 63.9 7 10.6 years (mean 7 s.d.); 87.8% RF-positive; mean Steinbrocker radiographic stage 3.2) or SLE (n ¼ 120, 92.6% women; age 36.6 7 12.7 years (mean 7 s.d.)) were part of the cohorts or from a single medical institute, respectively. For each individual, we used the maximum value of RF and antibody to DNA measured during the treatment period in the medical center or outpatient clinic. We detected antibody to CCP at a single time point using enzyme-linked immunosorbent assay, as previously described 38 .
Statistical analysis. We calculated LD index D (ref. 28 ) and drew Figure 1a using Excel software (Microsoft). We estimated haplotype frequencies using HAPLOTYPER software. We applied the w 2 test for contingency table tests for associations between allele-genotype distribution and phenotypes. FCRL3 expression in B cells and autoantibody production were regressed on the number of susceptible alleles (coded 0, 1 and 2). All other statistical analyses, unless otherwise stated, were done using STATISTICA software (StatSoft).
URLs. The JSNP database is available at http://snp.ims.u-tokyo.ac.jp/ index.html. TRANSFAC is available at http://www.gene-regulation.com/. HAPLOTYPER is available at http://www.people.fas.harvard.edu/~junliu/ Haplo/docMain.htm.
GenBank accession number. FCRL3 mRNA, NM_052939.
Note: Supplementary information is available on the Nature Genetics website. 
